The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.
Open accessAbstract
Lp[a] is a lipoprotein whose plasma concentration is highly correlated with cardiovascular disease. Its protein moiety, apoLp[a], consists of two large polypeptides, apo[a] and apo B. The possible contribution of Lp[a] to atherosclerosis in saphenous vein aortocoronary bypass grafts was studied in a population of patients undergoing coronary re-bypass surgery. The vein graft tissue levels of apoLp[a] were compared with graft duration, gross and light microscopic pathology, as well as plasma levels of apoLp[a]. The localization pattern of apo[a] and apo B in vein graft tissue was determined. In addition, the plasma levels of cholesterol, triglycerides, apoproteins (apo) A-I, A-II, and E were measured. In a representative subpopulation of 17 patients with a mean age of 63 years from whom grafts with a mean duration of 112 months were resected, the mean total plasma cholesterol level was 221 mg/dl, the mean high density lipoprotein cholesterol level was 31 mg/dl, and the mean plasma triglyceride level was 228 mg/dl. In normal saphenous veins, the level of apoLp[a] was below measurable limits (less than 2 ng/mg), and the level of apo B was very low (3.3 ng/mg). In resected grafts, the mean tissue level of apoLp[a] was 32 ng/mg, and that of apo B was 70 ng/mg, demonstrating the net accumulation of these apoproteins in veins from the time of their grafting into the arterial bed. The apoLp[a]/apo B ratio was determined in 77 tissue segments from 59 grafts (28 patients) and was found to be 0.313. This tissue ratio was significantly higher (p = 0.02) than the plasma apoLp[a]/apo B ratio from these patients, which was 0.132. Immunostaining showed co-localization of apo[a] and apo B in the neointima of grafts. The most abundant pathologic features observed in resected grafts were proliferated intima (43/52), thrombus (28/52), and atherosclerotic core regions (21/52). The level of tissue apo B correlated well with the abundance of core regions (r = 0.501), whereas the level of tissue apoLp[a] did not correlate as well with this feature (r = 0.233). Although apo[a] and apo B are almost absent from normal saphenous vein, these apoproteins (and presumably the lipoproteins Lp[a] and low density lipoprotein) accumulate in bypass vein grafts. The data support the view that these lipoproteins play a significant role in vein graft atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lytle, B. W., Loop, F. D., Cosgrove, D. M., Ratliff, N. B., Easley, K., & Taylor, P. C. (1985) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)38820-8 · Cited by 939
Dahlen, G. H., Guyton, J. R., Attar, M., Farmer, J. A., Kautz, J. A., & Gotto, A. M. (1986) · Circulation · doi:10.1161/01.cir.74.4.758 · Cited by 911
Self-citationArmstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H., & Seidel, D. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90099-7 · Cited by 626
CAMPEAU, L. A., Enjalbert, M., Lespérance, J., Bourassa, M. G., Kwiterovich, P. O., Wacholder, S., & Sniderman, A. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411223112101 · Cited by 621
Human plasma lipoprotein [a]. Structural properties.
Gaubatz, J. W., Heideman, C., Gotto, A. M., Morrisett, J. D., & Dahlen, G. H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32663-2 · Cited by 453
Self-citationPatsch, J. R., Karlin, J. B., Scott, L. W., Smith, L. C., & Gotto, A. M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1449 · Cited by 386
Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction
MURAI, A., MIYAHARA, T., FUJIMOTO, N., MATSUDA, M., & KAMEYAMA, M. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90048-1 · Cited by 383
HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY
Simpson, H. C. R., Meade, T. W., Stirling, Y., Mann, J. I., Chakrabarti, R., & Woolf, L. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91849-4 · Cited by 287
Radioimmunoassay of human plasma Lp(a) lipoprotein
Albers, J. J., Adolphson, J. L., & Hazzard, W. R. (1977) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41683-9 · Cited by 268
Cited by
Aortocoronary Saphenous Vein Graft Disease: Pathogenesis, Predisposition, and Prevention
Motwani, J. G., & Topol, E. J. (1998) · Circulation · doi:10.1161/01.cir.97.9.916 · Cited by 1,074
Brown, B. G., Zhao, X. Q., Sacco, D. E., & Albers, J. J. (1993) · Circulation · doi:10.1161/01.cir.87.6.1781 · Cited by 821
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 784
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Seed, M., Hoppichler, F., Reaveley, D., McCarthy, S., Thompson, G. R., Boerwinkle, E., & Utermann, G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005243222104 · Cited by 585
Lipoprotein (a). Heterogeneity and biological relevance.
Scanu, A. M., & Fless, G. M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114625 · Cited by 573
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)
Grainger, D. J., Kirschenlohr, H. L., Metcalfe, J. C., Weissberg, P. L., Wade, D. P., & Lawn, R. M. (1993) · Science · doi:10.1126/science.8503012 · Cited by 408
Suarna, C., Dean, R. T., May, J., & Stocker, R. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.10.1616 · Cited by 355
Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice
Grainger, D. J., Kemp, P. R., Liu, A. C., Lawn, R. M., & Metcalfe, J. C. (1994) · Nature · doi:10.1038/370460a0 · Cited by 352
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 335
Cox, J. L., Chiasson, D. A., & Gotlieb, A. I. (1991) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(91)90019-i · Cited by 333
Lipoprotein(a). A unique risk factor for atherothrombotic disease.
Loscalzo, J. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.5.672 · Cited by 296
F. T. G. O. C. I., Jaeger, B. R., Richter, Y., Nagel, D., Heigl, F., Vogt, A., Roeseler, E., Parhofer, K., Ramlow, W., Koch, M., et al. (2009) · Nature Reviews Cardiology · doi:10.1038/ncpcardio1456 · Cited by 294
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Atherogenesis in transgenic mice expressing human apolipoprotein(a)
Lawn, R. M., Wade, D. P., Hammer, R. E., Chiesa, G., Verstuyft, J. G., & Rubin, E. M. (1992) · Nature · doi:10.1038/360670a0 · Cited by 281
Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients.
Cressman, M. D., Heyka, R. J., Paganini, E. P., O'Neil, J., Skibinski, C. I., & Hoff, H. F. (1992) · Circulation · doi:10.1161/01.cir.86.2.475 · Cited by 281
Lipoprotein(a) and Atherosclerosis
Scanu, A. M., Lawn, R. M., & Berg, K. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-209 · Cited by 276
Harpel, P. C., Chang, V. T., & Borth, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10193 · Cited by 259
Gaubatz, J., Ghanem, K., Guevara, J., Nava, M., Patsch, W., & Morrisett, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42828-7 · Cited by 253
Self-citationCarmena, R., Lussier-Cacan, S., Roy, M., Minnich, A., Lingenhel, A., Kronenberg, F., & Davignon, J. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.1.129 · Cited by 31
Interaction of Lp(a) and of apo(a) with liver cells.
Kostner, G. M. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.7.1101 · Cited by 28
Enigmatic role of lipoprotein(a) in cardiovascular disease.
Anuurad, E., Enkhmaa, B., & Berglund, L. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00238.x · Cited by 14
Metadata
- Authors
- Cushing, G. L., Gaubatz, J. W., Nava, M. L., Burdick, B. J., Bocan, T. M., Guyton, J. R., Weilbaecher, D., DeBakey, M. E., Lawrie, G. M., & Morrisett, J. D.
- Venue
- Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
- Published
- 1989-09
- Volume
- 9
- Issue
- 5
- Pages
- 593-603
- ISSN
- 0276-5047 (ISSN-L)
- OpenAlex
- W2118721393
- Cited by
- 252
- References
- 21
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.